首页> 美国卫生研究院文献>Scientific Reports >Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer
【2h】

Poor prognostic value of lymphovascular invasion for pT1 urothelial carcinoma with squamous differentiation in bladder cancer

机译:pT1尿路上皮癌鳞状分化的淋巴管侵犯的预后价值低

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Lymphovascular invasion (LVI) is the primary and essential step in the systemic dissemination of cancer cells. The aim of our study was to assess the independent prognostic role of LVI for pT1 urothelial carcinoma with squamous differentiation in bladder cancer. We retrospectively analyzed the clinical and pathological information of 206 patients diagnosed pT1 urothelial carcinoma with squamous differentiation. Of the 206 patients, LVI was detected in 57 (27.6%) patients. The 5 year cancer specific survival (CSS) rates were 87.2% in LVI (−) and 52.4% in LVI (+) (p < 0.001). According to univariate analysis, tumor multiplicity, tumor size, recurrence and LVI were the prognostic factors associated with CSS. Additionally, tumor size and LVI significantly influenced the CSS in multivariate analysis. TURBT had shorter median CSS than RC in recurred patients with LVI (+). Our study suggested that LVI is an important predictor for survival of pT1 urothelial carcinoma with squamous differentiation. LVI positive status and tumor size ≥3 cm led to a higher risk of death. RC should be routinely performed in recurred LVI (+) bladder cancer patients of pT1 urothelial carcinoma with squamous differentiation.
机译:淋巴管浸润(LVI)是癌细胞全身性传播的主要步骤。我们研究的目的是评估LVI在膀胱癌中具有鳞状分化的pT1尿路上皮癌的独立预后作用。我们回顾性分析了206例诊断为pT1尿路上皮癌鳞状上皮癌的患者的临床和病理资料。在206位患者中,有57位(27.6%)患者检测到LVI。 LVI(-)和LVI(+)的5年癌症特异性生存率(CSS)分别为87.2%(p2.4 <0.001)。根据单因素分析,肿瘤的多发性,肿瘤的大小,复发和LVI是与CSS相关的预后因素。此外,在多变量分析中,肿瘤大小和LVI显着影响CSS。在复发的LVI(+)患者中,TURBT的中位CSS比RC短。我们的研究表明,LVI是具有鳞状分化的pT1尿路上皮癌生存的重要预测指标。 LVI阳性状态和肿瘤大小≥3cm导致更高的死亡风险。对于患有鳞状分化的pT1尿路上皮癌的复发LVI(+)膀胱癌患者,应常规进行RC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号